MedTrace Logo

Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

NCT02784964 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2021-07-15

No results posted yet for this study

Summary

1. To assess the safety of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis
2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis

Conditions

Interventions

BIOLOGICAL

Elixcyte 8 ml

ADSC 6.4\*10\^7 cells, allogeneic injection

DEVICE

Hya Joint Plus

Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.

BIOLOGICAL

Elixcyte 4 ml

ADSC 3.2\*10\^7 cells, allogeneic injection

BIOLOGICAL

Elixcyte 2 ml

ADSC 1.6\*10\^7 cells, allogeneic injection

Sponsors & Collaborators

  • A2 Healthcare Taiwan Corporation

    collaborator INDUSTRY

  • UnicoCell Biomed CO. LTD

    lead INDUSTRY

Principal Investigators

  • Yu-Han Chang, MD · Chang Gung Memorial Hospital

  • Cheng-Fong Chen, MD · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-07-31
Completion
2021-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784964 on ClinicalTrials.gov